Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Daniel Duprez,
Despite the fact that treatment of arterial hypertension has been more successful in the last decade, there is more evidence that cardiovascular protection can been be improved beyond lowering absolute blood pressure numbers. Arterial stiffness is an independent predictor for cardiovascular morbidity and mortality. The future direction in hypertension needs to be focused on maintaining vascular health and thus the arterial system next to blood pressure numbers.
Blood pressure is a powerful cardiovascular risk factor that acts on the arterial wall and is responsible in part for various cardiovascular events, such as heart failure, ischemic heart disease and cerebrovascular accidents (1). In clinical practice, 2 specific and arbitrary points of the blood pressure curve, peak systolic blood pressure and end-diastolic blood pressure, are used to define the cardiovascular risk factor. Because the goal of drug treatment in hypertension is to prevent cardiovascular complications, it appears likely that the totality of the blood pressure curve, not simply peak systolic blood pressure and end-diastolic blood pressure, should be considered to act mechanically on the arterial wall and therefore should be used to propose an adequate definition of high blood pressure (2).
Structural and functional properties of the arterial wall are altered in hypertension even at the early stages of the disease (3). Arterial stiffness is the most important cause of increasing systolic and pulse pressure, and for increasing pulse pressure with aging. Pulse pressure alone is inadequate to assess arterial stiffness accurately. Problems include the ‘normal’ amplification of the pressure wave as it travels from the aorta to the periphery. The arterial pressure wave has two principal components—the wave generated by the heart, which travels away from the heart, and the reflected wave, which returns to the heart from peripheral sites, predominantly in the lower part of the body.
Morbidity and mortality associated with hypertension are primarily related to arterial damage and may affect one or several organs. Considering the potential implications of arterial assessment in the prevention of cardiovascular disease, evaluation of the arterial effects of antihypertensive treatment is recommended (4).
Abnormalities of the arterial vasculature that precede cardiovascular morbid events are likely to occur in a temporal sequence (5). The initial abnormalities appear to be functional, in large part related to endothelial dysfunction associated with decreased bioavailability of nitric oxide (6). A decrease in constitutive release of nitric oxide, which maintains low small artery tone, may be the initial abnormality, but it is soon accompanied by a decrease in stimulated release of endothelial vasodilators, as manifested by a reduction in flow mediated dilation of conduit arteries. These functional abnormalities of the vasculature precede and are mechanistic precursors of the structural alterations that are responsible for thickening of the conduit artery wall, increases in pulse pressure, and atherosclerotic plaque development. These structural changes may also result in additional functional abnormalities.
Noninvasive measurement of arterial stiffness entails measurement of surrogate parameters that are intrinsically associated with stiffness. This involves three main methodologies:
The hope for the future is that a practical noninvasive screening technique will be used to assess the function and structure of the arterial wall in subjects with hypertension or even subjects at risk of developing hypertension. The effect of antihypertensive therapy on the functional and structural vessel wall abnormality can then be monitored during therapeutic intervention (8). Thus, a drug regimen that does not favorably affect the arterial structure or function in a given patient would be replaced by another drug regimen that might be more effective. The correction of the arterial wall abnormality could then serve as a guide to therapeutic efficacy rather than the absolute level of blood pressure, which now serves as the surrogate marker. How the blood pressure changes and the arterial wall changes might relate needs to be intensively studied.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Cohn JN. Arteries, myocardium, blood pressure and cardiovascular risk towards a revised definition of hypertension. J Hypertens 1998;16:2117–2124. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9886906&query_hl=3&itool=pubmed_docsum
2. Duprez DA, Kaiser DR, Whitwam W, Finkelstein S, Belalcazar A, Patterson R, Glasser S, Cohn JN. Determinants of radial artery pulse wave analysis in asymptomatic individuals. Am J Hypertens 2004;17:647-653. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15288881&query_hl=5&itool=pubmed_docsum
3. Duprez DA, Cohn JN. Monitoring vascular health beyond blood pressure. Curr Hypertens Rep 2006 (in press)
4. Cohn JN, Duprez DA, Grandits GA. Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment. Hypertension. 2005;46:217-220. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15867132&query_hl=8&itool=pubmed_docsum
5. Duprez DA, Somasundaram PE, Sigurdsson G, Hoke L, Florea N, Cohn JN. Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. J Hum Hypertens. 2005;19:515-519. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15905893&query_hl=10&itool=pubmed_docsum
6. McVeigh GE, Plumb R, Hughes S. Vascular abnormalities in hypertension: cause, effect, or therapeutic target? Curr Hypertens Rep. 2004;6:171-176. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15128467&query_hl=12&itool=pubmed_docsum
7. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens. 2002;15:426-444. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12022246&query_hl=14&itool=pubmed_docsum
8. Mahmud A, Feely J. Antihypertensive drugs and arterial stiffness. Expert Rev Cardiovasc Ther. 2003;1:65-78.
Daniel A Duprez, MD, PhD, FESC, FAHA, FACC Professor of Medicine Director Lipid Clinic Director of Research of the Rasmussen Center for Cardiovascular Disease Prevention
Associate Director of the Cardiovascular Clinical Trial Center Cardiovascular Division, University of Minnesota e-mail: email@example.com